Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing
Express News | Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of PAS-004
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europ
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA) today announced that its meeting of stockholders, which had been
Pasithea Therapeutics Announces Results From 2023 Annual Meeting
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 From NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced positive preclinical results from two in vivo studies evaluating the anti-tumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ: KTTA), today announced that its annual meeting of stockhol
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting With FDA for PAS-004 Clinical Development
-- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and NF1 mutations --
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody That Targets Α5β1 Integrin for the Treatment of Both Sporadic and Familial ALS
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of ALS ---- Fully humanized anti-α5β1 monoclonal antibody is ready for manufactu
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pa
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for Its Common Stock at Price of $0.70 per Share in Cash
Tender Offer Expected to Close Third Quarter of 2023PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotech
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid From Lucy Scientific Discovery, Inc.
PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of
Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of Its Board of Directors
Special Committee Continues to Actively Evaluate Unsolicited Proposal from Lucy Scientific Discovery Inc.PALO ALTO, Calif. and MIAMI, June 30, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (N
Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal From Lucy Scientific Discovery Inc.
Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, resear
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
– Prof. Steinman's groundbreaking research linking Epstein-Barr virus to multiple sclerosis named a runner-up for the 2022 Science Magazine Breakthrough of the Year –PALO ALTO, Calif. and MIAMI, Fla.,
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of
No Data